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Objectives: To evaluate the effectiveness of a prevention programme against the vertical transmission of HIV in
a resource-limited setting and to investigate variables associated with compliance.
Patients and methods: The Kento-Mwana project (2005–2008) provided counselling, serological and biomole-
cular testing and prophylaxis/therapy to HIV-positive pregnant women and their children attending four ante-
natal clinics in Pointe Noire, Republic of Congo. Expected and actual rates of vertical transmission of HIV were
compared. Univariate and multivariate analyses were performed in order to identify variables associated with
non-compliance.
Results: The observed transmission rate in the group who completed follow-up was 5/290 (1.7%, 95% CI
0.6%–4.1%). The overall estimated transmission rate in the target population, computed taking into
account the expected vertical transmission of HIV among drop-outs, was 67–115/638 (10.5%–18.0%). A com-
parison between this rate and the expected transmission rate in the absence of intervention (25%–40%)
showed that the programme was able to prevent approximately 50% of vertical transmissions. Older age
(OR 0.33, 95% CI 0.16–0.66, P¼ 0.002), telephone availability (OR 0.42, 95% CI 0.24–0.72, P¼ 0.002) and
occupation (OR 0.57, 95% CI 0.29–1.10, P¼ 0.092) were associated with better compliance.
Conclusions: Despite the vast majority of women accepting counselling and testing, many of them refused
prophylaxis or dropped out, thus reducing the effectiveness of the intervention from an ideal 2% to a still
important but less impressive median transmission rate of 15% (range 10.5%–18%). Promoting participation
and compliance, rather than increasing the potency of antiretroviral regimens, is crucial for preventing the ver-
tical transmission of HIV in Africa.
Keywords: PMTCT, mother-to-child transmission, drop-out, attrition, lost to follow-up
Introduction
Several strategies have been developed in resource-limited set-
tings in order to prevent HIV mother-to-child transmission
(PMTCT). Different approaches can be applied, among which
are availability of antiretroviral (ARV) drugs, interventions
related to the social and environmental context and stability of
financial support. In recent years, the widespread use of a
triple antiretroviral regimen has allowed more effective PMTCT
interventions.1,2 Several studies have shown a transmission rate
of 2% in women who adhered to a complete clinical protocol,
including maternal ARV regimens, vaginal delivery and an appro-
priate feeding choice.3,4 However, in these studies, women who
did not accept the PMTCT protocol or were lost to follow-up
were often excluded from the analyses;1,3 – 5 as a result, it is
often difficult to appreciate the overall effectiveness of these pre-
vention programmes when deployed in the real world.
In this article, we present the results of a programme to
prevent the vertical transmission of HIV based on a triple anti-
retroviral regimen in a resource-limited setting in the Republic
of Congo, Africa, in terms of feasibility and effectiveness. The
primary objective was to evaluate the impact of the clinical inter-
vention on the overall target population, defined as all pregnant
women who attended the healthcare units involved in the
Kento-Mwana PMTCT project during the study period. Secondary
objectives were to evaluate the clinical, demographic, social
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and behavioural factors associated with the risk of being lost to
follow-up.
Patients and methods
Study design, participants and setting
We enrolled in a prospective uncontrolled interventional study (the
Kento-Mwana project) all pregnant women who were attending four
antenatal care units located at the Army Hospital in Pointe Noire, Repub-
lic of Congo, and in the districts of Ndaka Susu, Mbota and Ngoyo on the
outskirts of the city, between September 2005 and December 2008.
Follow-up of the mother and child pairs was terminated on 31 December
2010. The entire programme was carried out at the peripheral local care
units. Voluntary counselling and testing for HIV infection was suggested
to each pregnant woman at the first visit. If this was refused or omitted,
the counselling was repeatedly offered by the midwife during the following
visits. Those who accepted the offer received serological screening for HIV,
as previously described.6 If an HIV-positive status was identified, a global
intervention for the prevention of vertical transmission of HIV was offered.
The delivery and follow-up of the children were also carried out in local
reference hospitals (the Army Hospital and Tie Tie Hospital).
Ethical approval and data collection
The study was conducted in accordance with the Declaration of Helsinki
and was approved by the Congolese Ministry of Health and the Congolese
Council against AIDS, who regularly supervised the project’s activities. All
participants provided written informed consent or an equivalent. With
women who were illiterate, the text of the consent was read by the phys-
ician or by the counsellor and translated into local idioms if needed. Con-
fidentiality was maintained throughout all phases of the study. A code
was assigned to each woman at the counselling step. The code included
two letters referring to the local health structure (e.g. NS for Ndaka Susu
care unit), a progressive number (e.g. 0001) and a letter (F for women
and E for newborns). This code was universal and was used throughout
the intervention, including for the laboratory tests. The name of the
patient (woman or infant) was written only in the clinical record and
was known only by the counsellor and the physician. Clinical records
were securely stored behind a locked door, in the counsellor’s office. Clin-
ical data were collected by the Italian physicians using an Excel data-
base. Only the code was reported.
Intervention protocol
The prophylactic intervention included a maternal ARV regimen, perinatal
prophylaxis for the mother and child and postnatal support according to
feeding choice. Women received triple zidovudine/lamivudine/nevirapine
therapy. If anaemia (haemoglobin ,8 g/dL) was present, zidovudine was
replaced by stavudine. If toxicity with nevirapine or drug interactions oc-
curred, a double-ARV regimen with two nucleoside reverse transcriptase
inhibitors (NRTIs) was offered. If the maternal T lymphocyte CD4+ (CD4)
cell count at the first visit was ,350 cells/mm3, the ARV regimen was
started immediately and continued after delivery and weaning. If the CD4
cell count at the first visit was .350 cells/mm3, the ARV regimen was
started at the 28th week of gestation and stopped after delivery or after
complete weaning in the case of formula or breast feeding, respectively;
nevirapine was discontinued first, followed by the two NRTIs 2 weeks later.
Vaginal delivery was routinely performed, unless obstetric conditions
required caesarean section. Vaginal washing with chlorhexidine (once,
before fetal expulsion) was used, and all invasive procedures such as
vacuum extraction, forceps or induced amniorrhexis were avoided when-
ever possible. All the mothers at the onset of the labour and their
newborn infants at birth received a single dose of oral nevirapine. In
addition, all the mothers received one tablet of zidovudine 300 mg
every 3 h from the onset of labour until umbilical cord clamping while
continuing the ARV regimen started during pregnancy. All the infants
also received zidovudine (4 mg/kg) twice daily from birth to the age of
4 weeks.
All the women were counselled on infant feeding options (exclusive
formula feeding or exclusive breast feeding). If chosen, formula milk
and clean water were provided. With exclusive breast feeding, the mater-
nal ARV regimen was continued regardless of the maternal CD4 cell
count, and weaning was performed at 6 months.
At the first visit, demographic, social and behavioural characteristics,
including age, nationality, housing conditions, telephone connection,
occupation, marital status, number of children, number of people living
in the house, disclosure of HIV-positive status to somebody else, use of
condoms, number of sexual partners, previous HIV tests and known HIV-
positive status, were collected in individual clinical records. All women
were seen every 2 weeks for the delivery of ARV drugs and physical exam-
ination for possible signs of disease or toxicity. Adherence to the drug
regimen was monitored by maternal self-report and pill count and was
defined as follows: A, ARVs were never stopped; B, ARVs were stopped
for fewer than 15 days; C, ARVs were stopped for more than 15 days.
Women were defined as being lost to follow-up during pregnancy or
after delivery if they did not return before the expected delivery date or
before the end of follow-up, respectively.
Laboratory methods
Haematological and biochemical assays were performed at the central
laboratory of the Army Hospital. Blood specimens were conveyed daily
from the peripheral healthcare units to the project’s central laboratory
at the Army Hospital in Pointe Noire.
A complete blood count, CD4+, CD8+ and CD3+ cell count (FACS-
Count, BD) and chemical analysis including alanine aminotransferase,
aspartate aminotransferase and blood glucose level were obtained at
baseline, 6 weeks after starting the ARV regimen, at the baby’s birth
and 3 months after delivery. Alanine aminotransferase and aspartate
aminotransferase were also checked 2 weeks after starting nevirapine
(before increasing the dose of nevirapine) and if clinical signs of hepatic
or skin toxicity appeared.
Infants born to HIV-infected women were followed at birth and at 1,
3, 4, 6, 8, 12, 14, 24, 26, 48 and 72 weeks after birth to be clinically exam-
ined for possible signs of disease or toxicity. A complete blood cell count
was performed at birth and at 4, 8, 12, and 24 weeks.
Infants were tested for HIV-1 infection at birth and at 4, 12 and
24 weeks (as well as at 8 weeks after complete weaning if applicable)
using DNA proviral PCR, as previously described.7 Positive specimens
were confirmed by testing a new blood specimen at the next visit. The
child was defined as being HIV infected if two positive specimens were
obtained. A further confirmation of HIV status was performed at 12
and 18 months by serological methods (Genscreen Plus HIV Ag/Ab EIA
by BIO-RAD, Marne la Coquette, France; Vironostika HIV Ag/Ab Uni-Form
EIA, bioMe´rieux Laboratories, Boxtel, NL, USA).
Formula-fed infants were defined as not being infected with HIV if
they tested negative on two PCR tests, both performed after 4 weeks
of life. With breast feeding, an additional PCR 8 weeks after completion
of weaning was required to assess the HIV-negative status.
Statistical analysis
The effectiveness of the intervention in terms of a reduction in the inci-
dence of vertical transmission of HIV was evaluated by comparing the
overall transmission rate expected in the target population without the
intervention with the actual vertical transmission rate of HIV observed
with the intervention. The target population was defined as all pregnant
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women who attended the four antenatal clinics during the study period.
The total number of HIV-positive pregnant women was estimated by as-
suming that the seroprevalence of HIV among the women who refused
counselling and testing was identical to that observed in the women
who were tested. Based on previous reports, with reference to the cultural
and social attitudes concerning feeding choice in the intervention area, the
transmission rate in HIV-positive women in the absence of any interven-
tion was estimated to be 25%–40%, according to the rates of transmis-
sion in the placebo arms of the major published studies.1,8,9 The same
rate of vertical transmission was assumed to exist in the HIV-positive
women who refused counselling and testing or prophylaxis, and in the
women lost to follow-up during pregnancy before starting ARV. In the
women lost to follow-up after the start of the ARV protocol, during preg-
nancy or after delivery, the transmission rates of HIV were assumed to
be 15%–35% and 6%–20%, respectively.8,10
In order to minimize bias, two authors (F. B. and A. C.) worked independ-
ently in performing the literature search in order to estimate the transmis-
sion rates in the different subgroups. Once each author had made his
estimations, we consulted as a team (F. B., A. C. and P. B.) to achieve a con-
sensus regarding the assumptions. In particular, in relation to the transmis-
sion rate among the women lost to follow-up, the estimates took into
account the wide range of behaviours observed in these women, ranging
from a few weeks of prophylaxis during early pregnancy to an almost com-
plete compliance with the protocol except for assessment of the infant’s
HIV status.8,10 The range of estimated and assumed transmission rates
was used in sensitivity analyses to evaluate the potential impact of the un-
certainties related to the rates of transmission on the overall estimates of
the programme’s effectiveness. The total number of potentially HIV-
positive children in the study population was estimated by adding up the
number of cases actually observed among the women who completed
the follow-up and the estimated number for the different groups of
women who dropped out. The number of children in whom HIV-positivity
was potentially averted by the intervention delivered to the total target
population was calculated as the difference between this number and
the expected number of cases in the absence of any intervention.
Among the HIV-positive women, factors evaluated for their associ-
ation with compliance with follow-up were age, nationality, gestational
age, housing conditions (building material, availability of running water
and electricity), telephone connection, occupation (housewife, student
or worker), marital status, number of children (dead and still alive),
number of people living in the house, disclosure of HIV-positive status
to somebody else, use of condoms, number of sexual partners, previous
HIV tests, known HIV-positive status, HIV-related conditions and clinical
conditions, according to the classification of the United States Centers
for Disease Control and Prevention (CDC). Univariate statistical analysis
was performed using the Mann–Whitney non-parametric test, x2 test
and x2 for trend. Stepwise multivariate logistic regression analysis was
performed, with loss to follow-up as the dependent variable, and all vari-
ables with a univariate P, 0.1 as covariates. The final model was arrived
at by means of a step-down procedure, based on the likelihood ratio test.
Results
Participants
Patient flow and results are summarized in Figure 1. A total of
13309 pregnant women attended the four antenatal clinics
for a scheduled visit during the study period. Of these, 98.9%
(13164/13309) agreed to be counselled, and 97.5% (12830/
13164) of these women agreed to be screened for HIV. Of
these, 4.8% (615/12830, 95% CI 4.4%–5.2%) were seropositive
for HIV-1. Of the seropositive women, 75.5% (464) agreed to be
included in the prophylactic intervention programme. In this
group, the median gestational age at the first visit was 23 weeks
(IQR 19–28 weeks), the median CD4 cell count was 290 cells/
mm3 (IQR 167–452 cells/mm3) and the median haemoglobin
level was 9.5 g/dL (IQR 8.5–10.5 g/dL). An HIV-related disease
was detected in 29.1% of the women (135/464), and 12.9% (60/
464) had an AIDS-defining condition; 18.1% (84/464) said they
had had an HIV test in the past, and 10.8% (50/464) declared them-
selves as being aware that the result of that had been positive.
ARV regimens, adherence to protocol, adverse events
and pregnancy outcome
From the first visit to the day of delivery, 8.8% (41/464) of the
women enrolled did not start prophylaxis (and were therefore con-
sidered to have been lost to follow-up), and 1.7% (8/464) had a still-
birth before beginning the ARV regimen. Of the remaining 415
women who actually started the ARV drugs, 88.7% (368/415)
were naive to any therapy. ARV drugs were given as prophylaxis
(32.1%; 133/415) or as therapy (56.6%; 235/415). Of the 11.3%
(47/415) women not naive to treatment, 6.8% (28/415) were
already on an ARV therapy when they came to their first visit,
whereas 4.6% (19/415) declared having started ARV drugs in the
past but then discontinuing them. Of these women, 1.2% (5/415)
had started ARV prophylaxis and 3.4% (14/415) ARV therapy.
Among the 415 women taking ARVs during pregnancy, 86.5%
(359/415) received zidovudine/lamivudine/nevirapine and 10.8%
(45/415) stavudine/lamivudine/nevirapine, whereas 2.7% (11/
415) received a regimen of two NRTIs. The median duration of
the ARV regimen during pregnancy was 77 days (IQR 50–
112 days). A modification of the ARV regimen was deemed
necessary in 16.1% (67/415) of the women: 43.3% (29/67) and
13.4% (9/67) for nevirapine- or zidovudine-related toxicity,
respectively, and 43.3% (29/67) for other reasons. Adherence
to ARV therapy or prophylaxis was classified as A (ARVs were
never stopped), B (ARVs were stopped for fewer than 15 days),
C (ARVs were stopped for more than 15 days) or not assessable
in 58.6% (243/415), 13.0% (54/415), 26.7% (111/415) and 1.7%
(7/415) of women, respectively. No death was associated with a
drug-related adverse event. Pregnancy was complicated by con-
firmed malaria in 26.3% of the women (109/415). As shown in
Figure 1, of the 415 women taking ARV drugs during pregnancy,
9.4% (39/415) were lost to follow-up before delivery, 4.8%
(20/415) had a stillbirth, 0.5% (2/415) died and 85.3% (354/
415) delivered a live-born infant.
Delivery and birth outcomes
Among women who received ARV during pregnancy, a total of
354 gave birth to 365 live-born infants (11 sets of twins). The
prophylactic protocol at delivery was correctly performed in
76.0% (269/354) of the cases. Premature rupture of membranes
was observed in 15.5% (55/354) of the women and obstetric
complications in 8.2% (29/354). The mean CD4 cell count at de-
livery was 452 cells/mm3 (IQR 273–587 cells/mm3) and the
mean haemoglobin value was 11.2 g/dL (IQR 10.1–12.4 g/dL).
The clinical characteristics of the 354 newborns evaluated are
described in Table 1. Exclusive formula feeding was chosen in
89.0% (315/354) of cases, exclusive breast feeding in 5.7%
(20/354) and a combination of the two options in 2.5% (9/
354). For 10 infants, the modality of feeding was not assessable.
As shown in Figure 1, among all the 354 children evaluated,
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81.9% (290/354) completed the follow-up, while 13.6% (48/354)
were lost to follow-up after delivery and 4.5% (16/354) died
before a final conclusion about their HIV status could be obtained.
The mean age at death was 21 days (IQR 2–98 days), and 56.3%
(9/16) of the newborns who died did so during the first 3 days of life.
HIV transmission and global performance of the
intervention
Five out of 290 children who completed the follow-up were diag-
nosed as being HIV positive, giving an observed transmission rate
of 1.7% (95% CI 0.6%–4.1%). None of the second twins
excluded from the analysis was diagnosed as being HIV infected.
The characteristics of mother and child pairs in which vertical
transmission of HIV occurred are described in Table 2. According
to our estimates (Figure 2), approximately 62–110 additional
infected children should have been born to women who eventu-
ally dropped out. This means that the overall estimated trans-
mission rate in the target population was 67–115 cases out of
638 children, i.e. 10.5%–18.0%. This number can be compared
with an expected transmission rate in the absence of the inter-
vention of 25%–40%, i.e. 160–255 cases. As a result, it can be
estimated that the intervention was able to prevent more than
one-half of the expected cases of vertical transmission.
Factors associated with the risk of being lost to follow-up
Table 3 reports univariate and multivariate analyses of the prob-
ability of not completing the programme (being lost to follow-
up). In the univariate analyses, declaring more than one sexual
13 309 Pregnant women attended antenatal clinics 145 Refused counselling
334 Refused HIV test
151 Refused protocol
41 LTFU During pregnancy
8 Had stillbirth
39 LTFU During pregnancy
2 Died
20 Had stillbirth
48 LTFU After delivery
16 Died
13 164 Pregnant women accepted counselling
12 830 Pregnant women accepted HIV test
615 HIV-Positive women
464 Accepted protocol
415 Took ARV during pregnancy
354 Had live-born infants
290 Completed follow-up
5 HIV-Positive infants
Observed HIV
transmission rate
98.9%
1.1%
2.5%
24.5%
8.8%
1.7%
9.4%
0.5%
4.8%
13.6%
4.5%
97.5%
4.8%
75.5%
89.4%
85.3%
81.9%
1.7%
Figure 1. Flow diagram reporting the number of women who were taking part in or had dropped out of the programme at each stage of the study,
from the target population to the group who completed the follow-up. The percentages refer to the number of women who had reached the
preceding stage. The final observed transmission rate of HIV refers to the 290 mother and child pairs who completed the follow-up and should
not be interpreted as an estimate of the overall transmission rate in the study population (see Figure 2). LTFU, lost to follow-up.
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partner appeared to be associated with a higher risk of being lost
to follow-up, while older age, better housing conditions (defined
as the availability of at least one of the following: running water,
electricity or a generator), telephone availability, occupation,
having disclosed the status of HIV seropositivity to somebody
else other than the partner, having been tested for HIV serology
in the past, being aware of seropositivity, co-habitation with
more than three people and a more severe CDC stage were all
associated with a lower risk of being lost to follow-up. When ana-
lysed in a multivariate model, only older age (group 26–30 years:
OR 0.33, 95% CI 0.16–0.66; group .30 years: 0.40, 95% CI
0.21–0.75; P¼ 0.002 for heterogeneity), telephone availability
(OR 0.42, 95% CI 0.24–0.72; P¼ 0.002) and occupation (OR
0.57, 95% CI 0.29–1.10; P¼ 0.092), albeit with a lower statistical
strength, remained significantly associated with the outcome.
Discussion
In agreement with other reports,2 – 4,10 these data confirm that
an exhaustive prophylactic protocol is effective in PMTCT in a
resource-constrained setting, with an observed vertical
transmission rate of less than 2% among women who fully
comply with the prevention programme.
In our study, the acceptance of voluntary counselling and
testing was satisfactory, and an optimal HIV vertical transmis-
sion rate was obtained in the mother and child pairs who com-
pleted the follow-up, when compared with other studies.11 – 13
However, the overall impact of this intervention was strongly
affected by the large number of women who refused to enter the
prophylactic protocol or dropped out, with an estimated trans-
mission rate for the whole target population of pregnant
women of 10.5%–18.0%. As a consequence, the programme
was able to prevent approximately 50% of cases of vertical
transmission. This is a noteworthy result, but it is much less
impressive than the 10–20-fold reduction that was observed
in the population who completed follow-up. Although the rates
of refusal and premature drop-out from the programme were
satisfactory when compared with other studies,14 – 19 their
impact on the overall effectiveness of the intervention was
critical. Indeed, according to our estimates, a large majority of
mother-to-child transmission of HIV occurs in these two
groups, and any intervention aimed at increasing the overall ef-
fectiveness of a prevention programme should be focused on
promoting participation in and compliance with the prevention
programme, rather than on increasing its efficacy among com-
pliers (e.g. with more effective drugs or caesarean section).
No previous study has used assumptions on the unobserved
proportions of infected women and the rates of transmission in
different subgroup to estimate the overall number of cases of
PMTCT occurring in the cohort and to compare them with the
number expected without the intervention, using sensitivity ana-
lyses. The most important source of potential error in our esti-
mates is the choice of expected HIV transmission rates in the
different groups of women. Notably, the estimated HIV transmis-
sion rate in women who refused the protocol or were lost to
follow-up accounts for the majority of the estimated HIV-
infected children. However, the impact of this potential bias is
balanced by the same uncertainty in estimating the vertical
transmission of HIV in the overall target population in the
absence of any intervention. The assumption related to the sero-
prevalence of women refusing counselling and testing, thought
to be arbitrary, is not critical due to the low refusal rate (,5%).
In fact, even if the seroprevalence in women refusing counselling
Table 2. Characteristics of mother-and-child pairs in which HIV vertical transmission occurred
Code
Maternal
ARV regimen
Duration of
ARV during
pregnancy,
days
Adherence
to ARV
regimen
Maternal CD4
at baseline,
cell/mm3 (%)
Maternal CD4
at delivery,
cell/mm3 (%)
Gestational
age at
delivery
Infant
weight at
birth, g
Infant age
at first positive
DNA PCR, days
Infant
status at
6 months
HM 0349 F AZT+3TC+NVP 33 C 370 (47) ND 41 3100 85 alive
NS 0479 F d4T+3TC+NVP 28 B 95 (17) 193 (19) 40 2790 48 dead
NS 1406 F AZT+3TC+NVP 8 A 137 (11) 136 (18) 40 3500 51 dead
NS 2013 F AZT+3TC+NVP 135 A 163 (12) 169 (23) 37 ND 192 alive
NS 2748 F AZT+3TC+NVP 243 A 233 (19) ND 34 1000 96 alive
All women were naive to the ARV regimen and all infants were exclusively formula fed.
AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; ND, not determined.
Table 1. Clinical characteristics of the 354 live-born infants included in
the analysis
Characteristic
Value [number (%) or
median (IQR)]
Male sex 176 (49.7)
Gestational age (weeks) 39 (38–40)
Premature (,37 weeks of gestation) 59 (16.6)
Very premature (,32 weeks of gestation) 11 (3.1)
Haemoglobin level (g/dL) 14.4 (12.6–15.9)
Birth weight (g) 2900 (2580–3200)
Very low birth weight (,2.5 kg) 54 (15.2)
Body length (cm) 49 (47–50)
Head circumference (cm) 33 (31–34)
Numbers and percentage or median value and interquartile range (IQR)
are shown for non-continuous and continuous variables, respectively.
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and testing is assumed to be three times the upper limit of
that observed among participating women, i.e. 15.6%, the
overall estimates of the efficacy of the intervention in terms of
the fraction of infants in whom HIV infection was prevented
should be only marginally affected (51% instead of 55%). In
addition, our assumption exactly overlaps with previous local
estimates.20
An ancillary source of bias is that a second test at the end of
pregnancy was not routinely offered in this programme and
information on women who seroconverted during pregnancy is
not available. Owing to this limitation, the overall impact of the
programme could be overestimated in our study.
The representativeness of the study population is another
important issue in this study. The whole population of pregnant
women expected to attend the 28 antenatal clinics of Pointe
Noire during the study period was approximately 110000 (un-
published data provided by the Congolese Ministry of Health).
As a consequence, the proportion of pregnant women attending
the four public antenatal clinics involved in the project should be
12% (13309/110000) of the total number of pregnant women
in the economic capital of the Republic of Congo, roughly equiva-
lent to the proportion of clinics (4/28¼14%) participating in the
study. This suggests, albeit indirectly, an acceptable representa-
tiveness of the study population.
Expected
transmission
without
intervention
Transmission
with
intervention
Observed data Estimated data
To
ta
l
To
ta
l
To
ta
l
Pregnant women
145 Refused
counselling
334 Refused
HIV test
151 Refused
protocol
41 LTFU‡
During pregnancy
before starting ARV
39 LTFU‡
During pregnancy
after starting ARV
48 LTFU‡
After delivery
290 Completed
follow-up
46 Stillbirths
or deaths
636–640
Overall estimated HIV transmission rate: 67–115/638 ¥ (10.5–18.0%)
*local abserved HIV seroprevalence **Computed as 615 diagnosed + 21–25 estimated HIV positive
  pregnant women ‡LTFU, lost to follow-up
WEstimated values are calculated based on literature data ¥638 as mean value of 636–640 estimated
  HIV positive pregnant women
12 830
Accepted
counselling
and HIV test
13 309
HIV-Positive
pregnant women
HIV-Infected
children
HIV
seroprevalence*
HIV
Transmission rateW
13 309 636–640** 25–40%
160–255
Expected number
of cases
25–40%
25–40%
25–40%
25–40%
15–35%
6–20%
1.7%
(95% CI: 0.6–4.1%)
(5/290)
-
1–3
38–60
4–7
10–16
6–14
3–10
5
-
67–115
Estimated number
of cases
4.8%
(95% CI: 4.4–5.2%)
4.8%
(95% CI: 4.4–5.2%)
6–8
15–17
4.8%
(95% CI: 4.4–5.2%)
4.8%
(95% CI: 4.4–5.2%)
(615/12.830)
Figure 2. Total number of cases of vertical transmission of HIV expected in the target population in the absence of any intervention, and the
estimated number of cases that actually occurred, based on observed data (white boxes) and on estimated (grey boxes) vertical transmission
rates of HIV at each stage of drop-out. See the text for underlying assumptions.
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Table 3. Univariate and multivariate analyses for loss to follow-up (LTFU)
Variable
LTFU group, n (%)
(n¼128)
Not LTFU group,
n (%) (n¼336)
P value
univariate
OR (95% CI)
univariate
OR (95% CI)
multivariate
Age (years) 0.002*
mean 27.8 29.7
median 27.4 29.7
Age (categories) 0.001**
≤25 years 47 (37) 69 (20) Ref. Ref.
26–30 years 31 (24) 117 (35) 0.39 (0.22–0.69) 0.33 (0.16–0.66)
.30 years 46 (36) 148 (44) 0.40 (0.21–0.75)
total 124 (97) 334 (99)
missing 4 (3) 2 (1)
Nationality 0.587**
Congolese 126 (98) 328 (98)
other 2 (2) 8 (2)
total 128 (100) 336 (100)
Gestational age (weeks) 0.119*
mean 24.4 23.4
median 24.0 23.0
Housing conditionsa 0.003**
none 58 (47) 103 (32) Ref.
at least one 66 (53) 220 (68) 0.53 (0.34–0.83)
total 124 (100) 323 (100)
Telephone ,0.001**
no 74 (58) 106 (31) Ref. Ref.
yes 54 (42) 230 (69) 0.34 (0.22–0.52) 0.42 (0.24–0.72)
total 128 (100) 336 (100)
missing 0 (0) 0 (0)
Occupation 0.006**
unemployedb 97 (76) 213 (63) Ref. Ref.
worker 24 (19) 106 (32) 0.50 (0.29–0.85) 0.57 (0.29–1.10)
total 121 (95) 319 (95)
missing 7 (5) 17 (5)
Marital status 0.296**
single 12 (9) 35 (10) Ref.
partner 82 (64) 185 (55) 0.50 (0.29–0.85)
husband 30 (23) 98 (29) 0.89 (0.39–2.08)
total 124 (96) 318 (94)
Number of children 0.445**
0–2 98 (76) 238 (71)
.2 28 (22) 93 (27)
total 126 (98) 331 (98)
missing 2 (2) 5 (2)
Number of people in the house 0.029**
0–2 59 (46) 181 (54) Ref.
.2 50 (39) 93 (27) 0.61 (0.38–0.98)
total 109 (85) 274 (81)
missing 19 (15) 62 (19)
Disclosed HIV-positivity to somebody 0.080**
none 87 (68) 205 (61) Ref.
partner 30 (23) 78 (23) 0.91 (0.54–1.52)
other 7 (5) 42 (12) 0.39 (0.15–0.96)
total 124 (96) 325 (96)
missing 4 (4) 11 (4)
Continued
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The above considerations underline the relevance of factors
associated with an increased probability of successfully complet-
ing the intervention, as these factors might help in focusing
future preventive programmes. In multivariate analyses, older
age, telephone availability and occupation (with a lower statistic-
al strength in multivariate analysis but significant in univariate
analysis, as shown in Table 3) were found to be predictors of
compliance with the programme. This is in agreement with
others’ experiences showing that young maternal age and a
lack of income-generating activity are significant risk factors
for declining ARV prophylaxis.21 – 24 Telephone availability has
been found to be associated with better compliance,25 – 28 both
making women easily reachable and reflecting a higher inde-
pendence. A limitation of this multivariate model is that many
of the variables are probably highly intercorrelated, and the
sample size is limited. For this reason, variables significant only
in the univariate analysis should also be discussed.
We found it particularly interesting that sharing information
on the HIV-positive status with the partner is not crucial in
women being lost to follow-up, while sharing this information
with a third party can be helpful for adhering to the clinical proto-
col. Discordant data are reported on this topic.29 – 31 In many
African countries, women known to be HIV infected are rejected
by their partner. For this reason, only a small percentage decide
to inform their partner. Another interesting finding was that the
gestational age at baseline was not significant in the loss to
follow-up, in contrast with recent experience21 and WHO recom-
mendations.32 This might be explained by the fact that the gap
between enrolment and starting ARV prophylaxis was filled,
in our intervention, by monthly clinical consultations with the
administration of ferrous sulphate and folic acid. In the context
of a PMTCT programme, all the identified risk factors should be
taken into consideration when scoring all women at the first
visit. Attention should be focused on women classified as being
Table 3. Continued
Variable
LTFU group, n (%)
(n¼128)
Not LTFU group,
n (%) (n¼336)
P value
univariate
OR (95% CI)
univariate
OR (95% CI)
multivariate
Use of condoms 0.163**
no 59 (46) 178 (53) Ref.
yes 60 (47) 134 (40) 1.35 (0.87–2.11)
total 119 (93) 312 (93)
missing 9 (7) 24 (7)
More than one sexual partner 0.060**
no 12 (9) 15 (4) Ref.
yes 82 (64) 218 (65) 2.13 (0.89–5.06)
total 94 (73) 233 (69)
missing 34 (27) 103 (31)
Previous HIV test 0.053**
no 16 (12) 68 (20) Ref.
yes 112 (88) 268 (80) 0.56 (0.30–1.05)
total 128 (100) 336 (100)
missing 0 (0) 0 (0)
Known HIV-positive status 0.001**
no 3 (23) 47 (71) Ref.
yes 10 (77) 19 (29) 0.12 (0.02–0.56)
total 13 (100) 66 (100)
HIV-related conditions 0.483**
no 34 (26) 101 (30) Ref.
yes 92 (73) 232 (69) 0.85 (0.52–1.37)
total 126 (99) 333 (99)
missing 2 (1) 3 (1)
CDC classificationc 0.067***
A 98 (76) 233 (69) Ref.
B 19 (15) 53 (16) 0.85
C 11 (9) 50 (15) 0.52
*, Mann–Whitney test; **, x2 test; ***, x2 test for trend.
Only maternal variables in which the univariate P,0.1 were included as covariates in the stepwise multivariate logistic regression.
Ref., reference.
a Availability of running water, electricity and generator.
b Housewife or student.
c Clinical classification of US CDC.
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at higher risk of giving up the programme, providing them with
stronger psychosocial support.
Unfortunately, no analysis could be carried out for women
who tested HIV positive but refused the protocol; these women
could have provided useful information,33,34 but the collection
of personal data in clinical records was performed only after ac-
ceptance of the study intervention and the provision of informed
consent. However, qualitative information on the attitudes of the
women who refused the intervention was collected during the
study period by the counsellors and the physicians. These atti-
tudes can be summarized as follows: fear of disclosure to the
partner, distrust in European health science and an unwillingness
to believe that an HIV-infected individual could be apparently in
good health. In addition, other factors that were neither col-
lected nor analysed may have played a role in determining the
loss to follow-up.
In conclusion, two strategies to improve the effectiveness of a
PMTCT programme can be recommended. First, improving
women’s awareness of the importance of a PMTCT intervention
in order to preserve their health and to give birth to an HIV-
negative baby should be the focus of the initial contacts, in
order to improve compliance in the subsequent phases. In fact,
a high acceptance rate of voluntary counselling and testing
may conceal a low awareness among women when making
this choice, creating the premise for a subsequent refusal or
drop-out. Second, clinical, social and environmental conditions
associated with an increased probability of premature termin-
ation of the programme need to be identified, in order to focus
and possibly tailor the intervention to women at increased risk
of not completing it.
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